Skip to content
DataLookout
Menu

QUESTNCT03431350

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 93 versions: 16 with changes below, 34 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Study completion pushed from Dec 31, 2026 to Dec 31, 2027
    • Site details revised at 1 of 50 sites
  2. Notable Eligibility criteria expanded, about 11 words
    • Primary endpoints: details revised at 4 of 11 entries
    • Secondary endpoints: details revised at 2 of 16 entries
    • Site details revised at 5 of 50 sites
  3. Minor Study sites revised (50)v87
  4. Minor Study completion date: Dec 31, 2025 to Dec 31, 2026v86
  5. Notable Phase: Phase 1/2 to Phase 2v81
Show 11 earlier versionsHide 11 earlier versions
  1. Minor Study completion date: Dec 31, 2024 to Dec 31, 2025v78
  2. Minor Study sites revised (50)v77
  3. Minor Study sites revised (50)v72
  4. Minor Study sites revised (50)v71
  5. Minor Study sites revised (50)v70
  6. Notable Results first posted: Nov 18, 2023v64
  7. Notable Primary endpoints: 9 to 11
    • Secondary endpoints: 7 to 16
    v63
  8. Minor Study completion date: Jul 1, 2023 to Dec 31, 2024v62
  9. Minor Study sites revised (50)v60
  10. Minor Study completion date: Jul 31, 2023 to Jul 1, 2023v56
  11. Minor Study completion date: Jan 31, 2023 to Jul 31, 2023
    • Study sites revised (50)
    v54
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Combination 1: Part 1: Number of Participants With Specified Toxicity
Timeframe: Cycle 1 (28 days)
Combination 1: Part 2: Objective Response Rate (ORR)
Timeframe: Up to 37 months
Combination 2: Composite Response Rate (RR)
Timeframe: Up to 31 months
Combination 1: Part 2: Number of Participants With Adverse Events (AEs)
Timeframe: Up to 37 months
Combination 2: Number of Participants With Adverse Events (AEs)
Timeframe: Up to 31 months
Combination 1: Part 2: Number of Participants With Adverse Events (AEs) of Grade >=3 Severity
Timeframe: Up to 37 months
Combination 2: Number of Participants With Adverse Events (AEs) of Grade >=3 Severity
Timeframe: Up to 31 months
Combination 3: Maximum Observed Plasma Concentration (Cmax) of Niraparib and Abiraterone Acetate After a Single Dose
Timeframe: Pre-dose, 30 min, 1 hour (hr), 1.5 hr, 2hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 24 hr, 48 hr, 72 hr, and 168 hr post dose on Day 1
Combination 3: Maximum Observed Plasma Concentration (Cmax) of Niraparib Normalized by the Dose(Niraparib) (Cmax/Dose) of Niraparib Administered With AA After a Single Dose
Timeframe: Pre-dose, 30 min, 1 hour (hr), 1.5 hr, 2hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 24 hr, 48 hr, 72 hr, and 168 hr post dose on Day 1
Combination 3: Area Under the Plasma Concentration-Time Curve From Time Zero to 168 Hours (AUC [0-168hr]) of Niraparib Administered With AA After a Single Dose
Timeframe: Pre-dose, 30 min, 1 hour (hr), 1.5 hr, 2hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 24 hr, 48 hr, 72 hr, and 168 hr post dose on Day 1
Combination 3: Area Under the Plasma Concentration-Time Curve for Niraparib From Time Zero to 168 Hours (AUC [0-168 Hours]/Dose) of Niraparib Administered With AA After a Single Dose
Timeframe: Pre-dose, 30 min, 1 hour (hr), 1.5 hr, 2hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 24 hr, 48 hr, 72 hr, and 168 hr post dose on Day 1

Secondary (16)

Combination 1: Parts 1 and 2: Plasma Concentrations of Niraparib
Combination 1: Parts 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Niraparib
Combination 1: Parts 1 and 2: Time to Reach the Maximum Plasma Concentration (Tmax) of Niraparib
Combination 1: Parts 1 and 2: Minimum Observed (Predose) Concentration Following Multiple Dosing (Ctrough) of Niraparib
Combination 1: Parts 1 and 2: Number of Participants With Anti-drug Antibodies of Niraparib
Show 11 moreShow less
Combination 1: Part 2 and Combination 2: Circulating Tumor Cells (CTC) Response
Combination 1: Part 2: Composite Response Rate
Combination 2: Objective Response Rate (ORR)
Combination 1: Part 2 and Combination 2: Duration of Objective Response
Combination 1: Part 2 and Combination 2: Overall Survival
Combination 3: Cmax of Niraparib and Abiraterone Acetate After a Single Dose For Low-strength FDC
Combination 3: Maximum Observed Plasma Concentration (Cmax) of Niraparib Normalized by the Dose(Niraparib) (Cmax/Dose) of Niraparib Administered With AA After a Single Dose for Low-strength FDC
Combination 3: Area Under the Plasma Concentration-Time Curve From Time Zero to 168 Hours (AUC [0-168hr]) of Niraparib Administered With AA After a Single Dose For Low-strength FDC
Combination 3: Area Under the Plasma Concentration-Time Curve for Niraparib From Time Zero to 168 Hours (AUC [0-168 Hours]/Dose) of Niraparib Administered With AA After a Single Dose For Low-strength FDC
Combination 3: Number of Participants With Adverse Events
Combination 3: Number of Participants With Clinical Laboratory Parameters

Arms and interventions

Combination 1:Dose Selection: Niraparib + cetrelimab (Part 1)Experimental

Dose regimen 1: The participants will receive niraparib 200 milligram (mg) orally once daily in combination with cetrelimab 240 mg intravenously (IV) once every 2 weeks. Dose regimen 2: The participants will receive niraparib 200 mg orally once daily in combination with cetrelimab 480 mg IV once every 4 weeks in 28-day treatment cycles until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. The safety evaluation team (SET) will determine if an additional cohort is necessary, based on the data from dose regimens 1 and 2. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.

Combination 1:Dose Expansion: Niraparib + cetrelimab (Part 2)Experimental

Participants will be assigned to either Cohort 1A (Biomarker \[BM\] positive \[+\]) or Cohort 1B (BM negative \[-\]) and will receive established RP2D of cetrelimab and niraparib, in Part 2 until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. A futility analysis will be performed for the Cohort 1B after 10 BM- participants are enrolled in Part 2. This cohort will be closed if the response is less than predetermined response rate as outlined in the protocol. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.

Combination 2: Dose Expansion: Niraparib + AA-P (Part 2)Experimental

Participants will be assigned to one of 4 cohorts based on biomarker status - Cohort 2A (BRCA biallelic loss), 2B (other DRD biallelic loss), 2C (BRCA monoallelic loss), or 2D (other DRD monoallelic loss), and will receive niraparib 200 mg once daily in combination with abiraterone acetate 1000 mg (4\*250 mg) plus 10 mg prednisone (5 mg twice daily) throughout treatment phase. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.

Combination 3: Niraparib + AA-PExperimental

Participants will be assigned to one of three cohorts to receive AA-P with or without niraparib. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.

Drugs: Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg, Abiraterone acetate 1000 mg, Prednisone 5 mg

Sites

50 sites in 7 countries

United States 19, Belgium 6, Spain 6, Israel 5, Italy 5, United Kingdom 5, Canada 4